We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Lineage Cell Therapeutics Inc (LCTX) NPV

Sell:$1.58 Buy:$1.61 Change: $0.16 (11.11%)
Market closed |  Prices as at close on 29 June 2022 | Switch to live prices |
Change: $0.16 (11.11%)
Market closed |  Prices as at close on 29 June 2022 | Switch to live prices |
Change: $0.16 (11.11%)
Market closed |  Prices as at close on 29 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. The Company designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has three allogeneic product candidates: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA). OPC1 is an oligodendrocyte progenitor cell therapy, which is in a follow-up for a Phase I/IIa multicenter clinical trial for spinal cord injuries (SCI). VAC is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells. Its VAC product candidates include, VAC2, which is in a Phase I clinical trial in non-small cell lung cancer (NSCLC).

Contact details

2173 Salk Ave Ste 200
United States
+1 (510) 5213390

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$242.71 million
Shares in issue:
169.73 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Brian Culley
    Chief Executive Officer, Director
  • Kevin Cook
    Chief Financial Officer
  • Gary Hogge
    Senior Vice President - Clinical and Medical Affairs
  • George Samuel
    General Counsel, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.